(Q3)Jan 31, 2024 | (Q2)Oct 31, 2023 | (Q1)Jul 31, 2023 | (FY)Apr 30, 2023 | (Q4)Apr 30, 2023 | (Q3)Jan 31, 2023 | (Q2)Oct 31, 2022 | (Q1)Jul 31, 2022 | (FY)Apr 30, 2022 | (Q4)Apr 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -29.41%-572K | 31.93%-985K | 15.86%-1.43M | 70.98%-4.75M | 99.52%-19K | 78.68%-442K | 77.77%-1.45M | 56.23%-1.7M | -1,185.94%-16.38M | -326.59%-3.92M |
Net income from continuing operations | 15.76%-1.95M | 34.08%-1.41M | 82.49%-4.84M | -150.48%-36.18M | -86.85%-4.11M | 47.14%-2.31M | 55.94%-2.13M | -809.40%-27.64M | 63.62%-14.45M | 93.52%-2.2M |
Operating gains losses | ---- | -98.89%1K | ---167K | 334.80%1.98M | 648.55%1.89M | ---- | 1,600.00%90K | ---- | -102.95%-842K | -101.24%-344K |
Depreciation and amortization | 896.21%1.32M | 143.08%316K | 142.25%344K | 43.12%634K | 63.83%231K | -7.04%132K | 27.45%130K | 146.06%142K | 137.08%443K | 191.23%141K |
Asset impairment expenditure | --0 | --0 | -89.17%2.75M | 12,402.44%25.63M | 28.78%264K | --0 | --0 | --25.37M | --205K | --205K |
Remuneration paid in stock | -179.02%-113K | 13.33%187K | 435.90%131K | -73.67%464K | -46.56%194K | -88.16%143K | 73.68%165K | -140.85%-39K | 342.78%1.76M | 280.24%363K |
Deferred tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---874K | ---- |
Other non cashItems | -93.20%72K | -88.66%60K | -9.45%575K | 69.44%2.56M | -363.12%-742K | 640.56%1.06M | -45.24%529K | 422.14%635K | -73.48%1.51M | -92.60%282K |
Change In working capital | -81.43%99K | 37.28%-143K | -32.12%-218K | 103.91%162K | 250.53%2.25M | -33.54%533K | 91.93%-228K | 73.33%-165K | -215.69%-4.14M | -137.42%-1.5M |
-Change in receivables | -71.58%79K | 109.09%22K | -82.69%-95K | -86.06%29K | -61.15%54K | 396.43%278K | -221.00%-242K | 72.22%-52K | 173.64%208K | 340.64%139K |
-Change in inventory | -58.82%7K | --0 | --0 | 893.94%262K | 30.81%259K | -81.72%17K | 92.62%-9K | 98.02%-4K | 82.57%-33K | 496.36%198K |
-Change in prepaid assets | -108.33%-32K | --0 | -129.72%-96K | 202.30%711K | 222.05%238K | 172.34%384K | 91.60%-67K | 105.19%323K | -527.52%-695K | -79,691.84%-195K |
-Change in payables and accrued expense | 130.82%45K | -283.33%-165K | 93.75%-27K | 60.34%-840K | 1,332.61%1.7M | -128.52%-146K | 104.28%90K | -11.62%-432K | -227.63%-2.12M | -105.30%-138K |
-Change in other working capital | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -160.00%-1.5M | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -29.41%-572K | 31.93%-985K | 15.86%-1.43M | 70.98%-4.75M | 99.52%-19K | 78.68%-442K | 77.77%-1.45M | 56.23%-1.7M | -1,185.94%-16.38M | -326.59%-3.92M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -894.12%-540K | 95.13%-50K | 91.56%-279K | 74.25%-5.06M | -54.84%-1.76M | 102.74%68K | 91.40%-1.03M | 19.57%-3.31M | -221.24%-19.66M | 66.03%-1.14M |
Net PPE purchase and sale | -66.02%-1.2M | --0 | 82.74%-39K | 78.47%-4.22M | 90.91%-155K | 27.82%-724K | 91.43%-1.11M | 92.20%-226K | -205.06%-19.58M | 47.65%-1.71M |
Net investment purchase and sale | --25K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net other investing changes | -19.57%637K | -158.82%-50K | 92.21%-240K | -945.68%-847K | -381.40%-1.6M | 153.66%792K | -91.82%85K | -153.78%-3.08M | -127.18%-81K | 767.87%570K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -894.12%-540K | 95.13%-50K | 91.56%-279K | 74.25%-5.06M | -54.84%-1.76M | 102.74%68K | 91.40%-1.03M | 19.57%-3.31M | -221.24%-19.66M | 66.03%-1.14M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 591.34%1.14M | 23.71%-74K | -80.82%1.66M | -61.37%8.31M | -104.09%-212K | -2.21%-231K | -100.83%-97K | 352.27%8.67M | -12.12%21.52M | -72.00%5.19M |
Net issuance payments of debt | 970.31%557K | -47.83%-34K | 6,243.75%1.97M | -100.67%-136K | -100.31%-17K | -42.22%-64K | -100.19%-23K | -26.96%-32K | 80.63%20.37M | -26.20%5.46M |
Net common stock issuance | ---- | --0 | --0 | --9.78M | ---- | ---- | --0 | --9.78M | --0 | --0 |
Cash dividends paid | --0 | ---- | --0 | --0 | --0 | --0 | ---- | --0 | --0 | --0 |
Proceeds from stock option exercised by employees | --0 | --0 | ---- | -98.92%27K | --0 | --0 | -96.44%18K | ---- | -80.12%2.49M | -100.01%-1K |
Interest paid (cash flow from financing activities) | 52.17%-33K | ---- | -66.67%-300K | 68.04%-402K | 64.88%-308K | 61.67%-69K | ---- | -928.57%-180K | 33.66%-1.26M | 35.33%-877K |
Net other financing activities | 723.47%611K | 56.52%-40K | 99.55%-4K | -1,133.77%-950K | -1,707.65%-9.66M | -366.67%-98K | 89.00%-92K | -19,265.28%-897K | 63.82%-77K | 2,059.95%601K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 591.34%1.14M | 23.71%-74K | -80.82%1.66M | -61.37%8.31M | -104.09%-212K | -2.21%-231K | -100.83%-97K | 352.27%8.67M | -12.12%21.52M | -72.00%5.19M |
Net cash flow | ||||||||||
Beginning cash position | --0 | -82.52%1.11M | -56.99%1.15M | -84.54%2.66M | 25.47%3.17M | -48.34%3.77M | -55.03%6.34M | -84.39%2.68M | 20,947.73%17.18M | 849.26%2.53M |
Current changes in cash | 103.80%23K | 56.87%-1.11M | -101.20%-44K | 89.65%-1.5M | -1,619.08%-1.99M | 87.34%-605K | 62.21%-2.57M | 160.34%3.66M | -184.94%-14.52M | -99.23%131K |
End cash Position | -99.27%23K | --0 | -82.52%1.11M | -56.59%1.15M | -56.59%1.15M | 25.47%3.17M | -48.34%3.77M | -42.88%6.34M | -84.54%2.66M | -84.54%2.66M |
Free cash from | -52.14%-1.77M | 61.51%-985K | 23.73%-1.47M | 75.06%-8.97M | 96.91%-174K | 62.09%-1.17M | 86.87%-2.56M | 71.62%-1.92M | -367.45%-35.96M | -267.95%-5.63M |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.